← All trials
NCT00127205
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2005
- Primary completion
- Jun 1, 2017
- Completion date
- May 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 5400
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Southwest Oncology GroupLead sponsor
- National Cancer Institute (NCI)Collaborator
- North Central Cancer Treatment GroupCollaborator
- Eastern Cooperative Oncology GroupCollaborator
- NSABP FoundationCollaborator
- University of ArizonaStudy chair
- Mayo ClinicStudy chair
- University of North Carolina at Chapel HillStudy chair
- University of WashingtonStudy chair
- University of CalgaryStudy chair
- University of Alabama, BirminghamStudy chair
- University of TorontoStudy chair
- Cancer and Leukemia Group B (CALGB)Collaborator
- Canadian Cancer Trials GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.